JP4659982B2 - カンデサルタン投与用経皮治療システム - Google Patents

カンデサルタン投与用経皮治療システム Download PDF

Info

Publication number
JP4659982B2
JP4659982B2 JP2000546761A JP2000546761A JP4659982B2 JP 4659982 B2 JP4659982 B2 JP 4659982B2 JP 2000546761 A JP2000546761 A JP 2000546761A JP 2000546761 A JP2000546761 A JP 2000546761A JP 4659982 B2 JP4659982 B2 JP 4659982B2
Authority
JP
Japan
Prior art keywords
transdermal therapeutic
therapeutic system
active ingredient
candesartan
copolymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000546761A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002513753A5 (enExample
JP2002513753A (ja
Inventor
トーマス・シュトゥリュングマン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hexal AG
Original Assignee
Hexal AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hexal AG filed Critical Hexal AG
Publication of JP2002513753A publication Critical patent/JP2002513753A/ja
Publication of JP2002513753A5 publication Critical patent/JP2002513753A5/ja
Application granted granted Critical
Publication of JP4659982B2 publication Critical patent/JP4659982B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2000546761A 1998-05-06 1999-05-04 カンデサルタン投与用経皮治療システム Expired - Fee Related JP4659982B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19820151A DE19820151A1 (de) 1998-05-06 1998-05-06 Transdermales therapeutisches System zur Anwendung von Candesartan
DE19820151.6 1998-05-06
PCT/EP1999/003029 WO1999056734A2 (de) 1998-05-06 1999-05-04 Transdermales therapeutisches system zur anwendung von candesartan

Publications (3)

Publication Number Publication Date
JP2002513753A JP2002513753A (ja) 2002-05-14
JP2002513753A5 JP2002513753A5 (enExample) 2010-03-11
JP4659982B2 true JP4659982B2 (ja) 2011-03-30

Family

ID=7866803

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000546761A Expired - Fee Related JP4659982B2 (ja) 1998-05-06 1999-05-04 カンデサルタン投与用経皮治療システム

Country Status (8)

Country Link
EP (1) EP1085858B1 (enExample)
JP (1) JP4659982B2 (enExample)
AT (1) ATE280575T1 (enExample)
AU (1) AU760550B2 (enExample)
BR (1) BR9910201A (enExample)
CA (1) CA2331414C (enExample)
DE (2) DE19820151A1 (enExample)
WO (1) WO1999056734A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60045211D1 (de) 1999-02-19 2010-12-23 Takeda Pharmaceutical Präparationen zur perkutanen aufnahme von zusammnesetzungen die einen angiotensin-ii-rezeptorantagonismus aufweisen
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
WO2005070463A2 (en) * 2004-01-12 2005-08-04 Sepracor, Inc. Compositions comprising (s)-amlodipine malate and an angiotensin receptor blocker and methods of their use
EP1711168A2 (en) * 2004-01-23 2006-10-18 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of candesartan cilexetil
EP1997479A1 (en) * 2007-05-31 2008-12-03 Helm AG Stabilized amorphous candesartan cilexetil compositions for oral administration
JP5308788B2 (ja) * 2008-11-27 2013-10-09 興和株式会社 貼付剤
CA2766120C (en) * 2009-07-07 2018-08-14 Convatec Technologies Inc. Amphiphilic silicone copolymers for pressure sensitive adhesive applications
CN104356116A (zh) * 2014-10-17 2015-02-18 北京理工大学 坎地沙坦有机胺盐及氨盐的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH674618A5 (enExample) * 1987-04-02 1990-06-29 Ciba Geigy Ag
US4898732A (en) * 1988-05-04 1990-02-06 The Clinipad Corporation Inhibiting of tumor growth with an antagonist of the renin-angioten-sin system
DE58906975D1 (de) * 1988-08-02 1994-03-24 Ciba Geigy Mehrschichtiges Pflaster.
ATE107517T1 (de) * 1989-05-25 1994-07-15 Takeda Chemical Industries Ltd Transdermales therapeutisches mittel.
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
GB2256135B (en) * 1991-05-31 1995-01-18 Orion Yhtymae Oy Transdermal administration of 4-substituted imidazoles
CA2115985A1 (en) * 1993-02-25 1994-08-26 Kohei Nishikawa Vascular hypertrophy suppressor
DE4341444C2 (de) * 1993-12-04 1996-03-14 Lohmann Therapie Syst Lts Wirkstoffhaltiges Pflaster und Verfahren zu seiner Herstellung
DE19512181C2 (de) * 1995-03-31 2003-11-06 Hexal Pharma Gmbh Transdermales System mit Ramipril und/oder Trandolapril als ACE-Hemmer
JPH08310946A (ja) * 1995-05-19 1996-11-26 Yuutoku Yakuhin Kogyo Kk 経皮吸収製剤
FR2735365B1 (fr) * 1995-06-14 1997-09-05 Sanofi Sa Utilisation d'un antagoniste de l'angiotensine ii et d'un derive du benzofurane pour la preparation d'un medicament utile dans le traitement des affections cardiovasculaires
FR2746013B1 (fr) * 1996-03-18 1998-05-29 Sanofi Sa Utilisation de composes antiarythmiques dans la prevention de la mortalite post infarctus
JP4346696B2 (ja) * 1996-05-28 2009-10-21 久光製薬株式会社 経皮治療用装置
DE19626621A1 (de) * 1996-07-02 1998-01-08 Hexal Ag Pflaster zur transdermalen Anwendung von Pergolid
JPH11315034A (ja) * 1998-03-04 1999-11-16 Takeda Chem Ind Ltd アンギオテンシンｉｉ拮抗作用を有する化合物の徐放性製剤、その製造法および用途

Also Published As

Publication number Publication date
EP1085858B1 (de) 2004-10-27
WO1999056734A3 (de) 2000-01-27
WO1999056734A2 (de) 1999-11-11
EP1085858A2 (de) 2001-03-28
DE59910944D1 (de) 2004-12-02
DE19820151A1 (de) 1999-11-11
CA2331414C (en) 2008-09-16
JP2002513753A (ja) 2002-05-14
AU3931199A (en) 1999-11-23
AU760550B2 (en) 2003-05-15
ATE280575T1 (de) 2004-11-15
BR9910201A (pt) 2001-01-09
CA2331414A1 (en) 1999-11-11

Similar Documents

Publication Publication Date Title
CA2667477C (en) Transdermal delivery of ketoprofen polar derivatives
JP5137286B2 (ja) フェンタニル含有口腔粘膜貼付剤
US20040253299A1 (en) Transdermal therapeutic system (reservoir-tts) for using pramipexole and ropinirole
JP2569396B2 (ja) 経皮投与型薬物用貼付剤
US20230139565A1 (en) Oral delivery system comprising hydroxychloroquine and/or chloroquine
JP4659982B2 (ja) カンデサルタン投与用経皮治療システム
CN111447926A (zh) 用于透皮施用胍法辛的包含至少一种添加剂的透皮治疗系统
CN111465392A (zh) 用于胍法辛透皮给药的含硅酮聚合物的透皮治疗系统
AU782487B2 (en) Transdermal therapeutic system for the delivery of lerisetron
WO2000048634A1 (fr) Preparations d'adsorption percutanee de compose ayant un antagonisme de recepteur d'angiotensine ii
US20230123388A1 (en) Transdermal and/or topical delivery system comprising hydroxychloroquine and/or chloroquine
AU6434000A (en) Transdermal therapeutic system for the utilization of tolterodine
JPH06256173A (ja) 医療用貼付剤
MXPA00010704A (en) Transdermal therapeutic system for the administration of candesartan
HK40084062A (en) Transdermal and/or topical delivery system comprising hydroxychloroquine and/or chloroquine
JP2000302695A (ja) アンジオテンシンｉｉ受容体拮抗作用を有する化合物の経皮吸収剤

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060427

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090917

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091020

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20091203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20091217

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20091217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20091203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100119

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20100119

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101207

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101228

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140107

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees